Adiponectin predicts the antioxidant capacity and size of high-density lipoprotein (HDL) in individuals with diabetes mellitus

Dias, G.D.; Cartolano, F.C.; Freitas, M.C.P.; Helena, Ernani Tiarajú de Santa; Markus, Marcello Ricardo Paulista; Santos, Raúl D.; Damasceno, Nágila Raquel Teixeira

doi:10.1016/j.jdiacomp.2021.107856

Cited by 11 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this context, it has been reported that adiponectin may increase HDL-cholesterol levels 25 , which could explain our findings. In addition, adiponectin improves HDL-cholesterol function and induces cellular cholesterol efflux, leading to the production of HDL-cholesterol particles through upregulation of ABCA1 and ABCG1 protein expression 26,27 . Therefore, adiponectin's mechanisms on HDL-cholesterol may have a protective effect against the transition from the MHO to MUO condition.…”

Section: Discussionmentioning

confidence: 99%

Adiponectin, but not leptin, is associated with the metabolically healthy obesity phenotype

Weyman-Vela,

Guerrero-Romero,

Simental-Mendía

2024

RME

View full text Add to dashboard Cite

Background: It is currently unknown whether high adiponectin or low leptin levels induce a favorable metabolic profile in the metabolically healthy obesity (MHO) phenotype. Objective: To determine the association between leptin and adiponectin levels with the MHO phenotype. Methods: Apparently healthy men and women aged 18 years or more with body mass index (BMI) ≥ 30 kg/m 2 were selected for a case-control study. Individuals with MHO were allocated to the case group while those with metabolically unhealthy obesity (MUO) were assigned to the control group. Results: A total of 76 individuals were enrolled and allocated into the groups with MHO (n = 38) and MUO (n = 38). The logistic regression analysis adjusted by age, sex, BMI, and waist circumference showed that fasting glucose (odds ratio [OR] = 0.87; 95% confidence interval [CI]: 0.80-0.93) and triglycerides (OR = 0.98; 95% CI: 0.98-0.99) are inversely associated with MHO, while adiponectin levels had a positive association (OR = 1.77; 95% CI: 1.31-2.38). However, leptin concentrations were not associated with MHO (OR = 0.97; 95% CI: 0.93-1.02). Conclusion: The adiponectin concentrations, but not leptin, are positively associated with the MHO phenotype.

show abstract

Section: Discussionmentioning

confidence: 99%

Adiponectin, but not leptin, is associated with the metabolically healthy obesity phenotype

Weyman-Vela,

Guerrero-Romero,

Simental-Mendía

2024

RME

View full text Add to dashboard Cite

show abstract

“…Resistin can reduce the uptake of glucose by adipose tissue and inhibit the signal transduction pathway of insulin [ 23 ]. Adiponectin can reduce the occurrence and development of diabetes by improving insulin sensitivity [ 24 ]. These results indicate that resveratrol has a dose-dependent effect on GDM rats to increase insulin secretion, reduce blood glucose, reduce body weight, and regulate blood lipids and plasma adipokines.…”

Section: Discussionmentioning

confidence: 99%

The Effect of Resveratrol on Blood Glucose and Blood Lipids in Rats with Gestational Diabetes Mellitus

Zhang

Wang²,

Ren

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. Previous studies have reported that resveratrol has various biological effects such as anti-inflammatory, antioxidant, and antitumor. This study aimed to investigate the effects of resveratrol on blood glucose and blood lipids in rats with gestational diabetes mellitus (GDM). Methods. The rat diabetes model was prepared by one-time intraperitoneal injection of streptozotocin (STZ, 35 mg/kg). Fasting blood glucose was measured by using a blood glucose meter. The ELISA method was used to detect the levels of insulin, leptin, adiponectin, resistin, TNF-α, and IL-6. The content of TC, TG, LDL-C, and HDL-C was determined by using an automatic biochemical detector. Results. Compared with the GDM group, the insulin level in the resveratrol (120 and 240 mg/kg) treatment group was significantly increased. But, the blood glucose level and body weight were significantly reduced. The content of TC, TG, and LDL-C in the resveratrol (240 mg/kg) treatment group was significantly reduced, and the content of HDL-C was significantly increased. In addition, leptin, resistin, TNF-α, and IL-6 levels in the 240 mg/kg resveratrol treatment group were significantly reduced, and adiponectin was significantly increased. Also, resveratrol (240 mg/kg) was stronger than metformin hydrochloride in improving insulin secretion and regulating blood lipids and adipokine content. Conclusion. Resveratrol has a dose-dependent effect on GDM rats to increase insulin secretion, reduce blood glucose and body weight, and regulate blood lipids and plasma adipokines.

show abstract

“…Adiponectin could increase fat metabolism, control insulin sensitivity, modify homeostasis, and regulate glucose tolerance to protect individuals from diabetes 135 . Not only lower antioxidant capacity but also a worse effect of type 2 diabetes mellitus on high‐density lipoprotein (HDL) functionality by rising APO AI, particle size, and cholesterol content, correlated with higher adiponectin 141 . Adiponectin knock‐out (Adp−/−) mice increased concentrations of TNFα and free fatty acid (FFA) by down‐regulating peroxisome proliferator‐activated receptor (PPAR)α levels, thus leading to insulin resistance 142 .…”

Section: Mechanismsmentioning

confidence: 99%

“… 135 Not only lower antioxidant capacity but also a worse effect of type 2 diabetes mellitus on high‐density lipoprotein (HDL) functionality by rising APO AI, particle size, and cholesterol content, correlated with higher adiponectin. 141 Adiponectin knock‐out (Adp−/−) mice increased concentrations of TNFα and free fatty acid (FFA) by down‐regulating peroxisome proliferator‐activated receptor (PPAR)α levels, thus leading to insulin resistance. 142 Adiponectin receptors (AdipoR) 1 and AdipoR2, respectively had a region‐specific effect on anxiety‐like behavior and fear memory extinction.…”

Section: Mechanismsmentioning

confidence: 99%

Neurological and metabolic related pathophysiologies and treatment of comorbid diabetes with depression

Li,

Yang,

Zhou

et al. 2023

CNS Neurosci Ther

View full text Add to dashboard Cite

BackgroundThe comorbidity between diabetes mellitus and depression was revealed, and diabetes mellitus increased the prevalence of depressive disorder, which ranked 13th in the leading causes of disability‐adjusted life‐years. Insulin resistance, which is common in diabetes mellitus, has increased the risk of depressive symptoms in both humans and animals. However, the mechanisms behind the comorbidity are multi‐factorial and complicated. There is still no causal chain to explain the comorbidity exactly. Moreover, Selective serotonin reuptake inhibitors, insulin and metformin, which are recommended for treating diabetes mellitus‐induced depression, were found to be a risk factor in some complications of diabetes.AimsGiven these problems, many researchers made remarkable efforts to analyze diabetes complicating depression from different aspects, including insulin resistance, stress and Hypothalamic–Pituitary–Adrenal axis, neurological system, oxidative stress, and inflammation. Drug therapy, such as Hydrogen Sulfide, Cannabidiol, Ascorbic Acid and Hesperidin, are conducive to alleviating diabetes mellitus and depression. Here, we reviewed the exact pathophysiology underlying the comorbidity between depressive disorder and diabetes mellitus and drug therapy.MethodsThe review refers to the available literature in PubMed and Web of Science, searching critical terms related to diabetes mellitus, depression and drug therapy.ResultsIn this review, we found that brain structure and function, neurogenesis, brain‐derived neurotrophic factor and glucose and lipid metabolism were involved in the pathophysiology of the comorbidity. Obesity might lead to diabetes mellitus and depression through reduced adiponectin and increased leptin and resistin. In addition, drug therapy displayed in this review could expand the region of potential therapy.ConclusionsThe review summarizes the mechanisms underlying the comorbidity. It also overviews drug therapy with anti‐diabetic and anti‐depressant effects.

show abstract

Adiponectin predicts the antioxidant capacity and size of high-density lipoprotein (HDL) in individuals with diabetes mellitus

Cited by 11 publications

References 25 publications

Adiponectin, but not leptin, is associated with the metabolically healthy obesity phenotype

Adiponectin, but not leptin, is associated with the metabolically healthy obesity phenotype

The Effect of Resveratrol on Blood Glucose and Blood Lipids in Rats with Gestational Diabetes Mellitus

Neurological and metabolic related pathophysiologies and treatment of comorbid diabetes with depression

Contact Info

Product

Resources

About